

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

SYH2051 (SELECTIVE ATM INHIBITOR) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.

The board of directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that SYH2051 (the “**Product**”) developed by the Group has been approved by the U.S. Food and Drug Administration (FDA) to conduct clinical trials in the U.S. The Product has also obtained approval from the National Medical Products Administration of the People’s Republic of China in June 2023 to conduct clinical trials in China.

The Product is a Class 1 chemical drug independently developed by the Group. As an ATM inhibitor, the Product selectively delays the repairing of DNA double-strand breaks through targeted inhibition of phosphorylation of ATM protein kinase and its downstream signaling proteins CHK2 and KAP1, causing persistent DNA double-strand breaks and ATM-mediated cell cycle arrest to inhibit the proliferation of tumor cells. The indication for this approval is advanced solid tumors. Preclinical studies demonstrated that the Product had good selectivity of ATM targets and exhibited excellent in vitro and in vivo activities, providing a promising clinical development value. The Product has completed a Phase Ia dose escalation trial of monotherapy in advanced solid tumors in China, obtaining the safety profile and human pharmacokinetic data for monotherapy. Currently, a series of clinical trials, including combination with radiotherapy, combination with antibody-drug conjugate (ADC), and combination with chemotherapy, are being actively carried out.

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dongchen
Chairman

Hong Kong, 13 March 2025

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin and Mr. CHEN Weiping as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as independent non-executive directors.